Disrupted molecular glue complex drives RAS inhibitor resistance
Ben Sang(Memorial Sloan Kettering Cancer Center), Piro Lito(Memorial Sloan Kettering Cancer Center), Arvin C. Dar(Memorial Sloan Kettering Cancer Center), Feng Hu(Memorial Sloan Kettering Cancer Center), Ling Feng Ye(Memorial Sloan Kettering Cancer Center), Antonio Cuevas-Navarro(Memorial Sloan Kettering Cancer Center), A Spira(Virginia Cancer Specialists), Alberto Vides(Memorial Sloan Kettering Cancer Center), Aaliyah Washington(Memorial Sloan Kettering Cancer Center), Kevin K. Lin(Revolution Medicines (United States)), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Aparna Hegde(Revolution Medicines (United States)), Brian M. Wolpin(Dana-Farber Cancer Institute), Salman R. Punekar(NYU Langone Health), Zheng Fu(Memorial Sloan Kettering Cancer Center), Ignacio Garrido-Laguna(University of Utah), David S. Hong(The University of Texas MD Anderson Cancer Center), Shijie Fan(Memorial Sloan Kettering Cancer Center), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Ethan Ahler(Revolution Medicines (United States)), Diego J. Rodriguez(Memorial Sloan Kettering Cancer Center), Yasin Pourfarjam(Memorial Sloan Kettering Cancer Center), Sumit Kar(Revolution Medicines (United States)), Jacqueline A.M. Smith(Revolution Medicines (United States))
Cited by 1
Related Papers
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
|Annual Review of Biochemistry|2011|391